Results 321 to 330 of about 16,465,333 (371)

Pulmonary Responses to Selective Phosphodiesterase-5 and Phosphodiesterase-3 Inhibitors

Chest, 2004
To compare the direct pulmonary vasodilating activity and specificity of phosphodiesterase-5 (zaprinast) and phosphodiesterase-3 (milrinone) inhibitors on the pulmonary vascular (PV) bed of the spontaneously breathing cat with an intact chest.Prospective, randomized animal study.Laboratory of university hospital.Experiments were performed in vivo in ...
Yaacov Gozal, Idit Matot
openaire   +3 more sources

Local Regulation of Tooth Mineralization by Sphingomyelin Phosphodiesterase 3

Journal of Dental Research, 2013
Sphingomyelin phosphodiesterase 3 ( Smpd3) encodes a membrane-bound enzyme that cleaves sphingomyelin to generate several bioactive metabolites. A recessive mutation called fragilitas ossium ( fro) in the Smpd3 gene leads to impaired mineralization of bone and tooth extracellular matrix (ECM) in fro/fro mice.
Marc D. McKee, Monzur Murshed, Sharifa Alebrahim, Faleh Tamimi, Hazem Eimar, Zohreh Khavandgar   +5 more
openaire   +4 more sources

The dual phosphodiesterase 3/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutants.

American Journal of Physiology - Lung cellular and Molecular Physiology, 2020
Over 2,000 mutations have been reported in the cftr gene, many of which cause disease but are rare and have no effective treatment. Thus, there is an unmet need for new, mutation-agnostic, therapies for cystic fibrosis (CF).
M. Turner, Yishan Luo, David Y. Thomas, J. Hanrahan   +3 more
semanticscholar   +1 more source

Phosphodiesterase 3 inhibitors boost bone outgrowth

bioRxiv
BACKGROUND AND PURPOSE C-type natriuretic peptide (CNP) stimulates skeletal growth by acting on the growth plates of long bones, and a CNP variant is clinically used for achondroplasia treatment.
Takaaki Kawabe, A. Ichimura, Tomoki Yasue, Jianhong Li, Ga Eun Kim, Haruki Ishikawa, Yohei Uda, Hiromu Ito, M. Nishi, Hiroshi Takeshima   +9 more
semanticscholar   +2 more sources

Tyrosyl‐DNA Phosphodiesterase (Tdp1) (3′‐Phosphotyrosyl DNA Phosphodiesterase)

2006
Tyrosyl-DNA phosphodiesterase (Tdp1) hydrolyzes 3'-phosphotyrosyl bonds in vitro. Because topoisomerase I, a type IB topoisomerase, is the only enzyme known to form 3'-phosphotyrosine bonds in eukaryotic cells, it was proposed that Tdp1 is involved in the repair of dead-end topoisomerase I-DNA covalent complexes that may form in vivo.
Alex B. Burgin, Amy C. Raymond
openaire   +3 more sources

Phosphodiesterase 3 (PDE3): Structure, Localization and Function

Cardiovascular & Hematological Agents in Medicinal Chemistry, 2009
Cyclic adenosine 3'5'-monophosphate (cAMP) and cyclic guanosine 3'5'-monophosphate (cGMP) are critical intracellular messengers involved in transduction of signals generated by a wide variety of extracellular stimuli, including growth factors, cytokines, peptide hormones, light and neurotransmitters.
Kasumi Shimizu, Toshiro Tagawa, Taku Murata, Kenichi Hiramoto   +3 more
openaire   +3 more sources

Expression of phosphodiesterase 3 in rat submandibular gland

Archives of Oral Biology, 2000
The expression of phosphodiesterase (PDE) 3 isoforms was investigated in extracts of rat submandibular gland by reverse transcription-polymerase chain reaction (RT-PCR) and the PCR fragments were then sequenced. PDE3 activity was detected in gland homogenates; about 90% of the activity was in the supernatant fraction and about 10% in the particulate ...
Toshifumi Sugatani, Taku Murata, Toshiro Tagawa   +2 more
openaire   +3 more sources

Biosynthesis of the Myelin 2′,3′‐Cyclic Nucleotide 3′‐Phosphodiesterases

Journal of Neurochemistry, 1990
Abstract:We have investigated the site of synthesis of the 2′,3′‐cyclic nucleotide 3′‐phosphodiesterases (CNPs I and II) in rat brain. Rapid kinetics of incorporation of CNPs into oligodendrocyte plasma membrane in the intact brain are consistent with their synthesis on free polysomes.
C S Gillespie, David R. Colman, L. Bernier, Peter J. Brophy   +3 more
openaire   +3 more sources

Reduced Phosphodiesterase 3 Activity and Phosphodiesterase 3A Level in Synthetic Vascular Smooth Muscle Cells: Implications for Use of Phosphodiesterase 3 Inhibitors in Cardiovascular Tissues

Molecular Pharmacology, 2002
Vascular smooth muscle cells (VSMC) in situ function to control contraction and are said to express a contractile phenotype. However, during development or in response to vascular damage, VSMC proliferate and express a more synthetic phenotype.
Heather A. Dunkerley, Daniel Palmer, Douglas G. Tilley, Hanguan Liu, Sandra L. Jimmo, Donald H. Maurice   +5 more
openaire   +3 more sources

Phosphodiesterase-3 inhibitor (cilostazol) attenuates oxidative stress-induced mitochondrial dysfunction in the heart

Journal of Geriatric Cardiology, 2014
Background Cilostazol is a type 3 phosphodiesterase inhibitor which has been previously demonstrated to prevent the occurrence of tachyarrhythmia and improve defibrillation efficacy.
S. Chattipakorn, Savitree Thummasorn, J. Sanit, N. Chattipakorn   +3 more
semanticscholar   +1 more source